Las Vegas, NV -- (SBWIRE) -- 01/02/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Cavium Inc(NASDAQ:CAVM), Silver Standard Resources Inc. (USA)(NASDAQ:SSRI), Sarepta Therapeutics Inc(NASDAQ:SRPT), Horizon Pharma Inc(NASDAQ:HZNP)
Cavium Inc(NASDAQ:CAVM) was a volume gainer of 1.56 million shares and the average volume of the stock remained 626,738.00 shares. The stock opened the session at $33.34 and finished at the end of the day at $34.51 and the stock escalated 3.51%.The market capitalization of the stock remained 1.79 billion. Cavium, Inc. designs, develops, and markets semiconductor processors for intelligent and secure networks. It offers integrated semiconductors that provide single or multiple cores of processors with intelligent layer 2 through 7 processing for enterprise network, data center, broadband and consumer, and access and service provider markets.
For How Long CAVM will fight for Profitability? Read This Trend Analysis report
In the preceding trading session, Silver Standard Resources Inc. (USA)(NASDAQ:SSRI) exchanged 1.55 million shares and the average volume remained 1.72 million shares. The stock closed the session at $6.96 with the gain of 2.96%. Silver Standard Resources Inc. engages in the acquisition, exploration, development, and operation of silver-dominant mineral properties principally in the Americas. It primarily explores for silver, zinc, gold, and lead deposits.
Will SSRI Continue To Move Higher? Find Out Here
Sarepta Therapeutics Inc(NASDAQ:SRPT) decreased -1.79% and its closing price was $20.37. The volume of the stock was 1.55 million shares and the average volume remained 2.17 million shares. The market capitalization of the stock remained 765.55 million. The beta of the stock remained 0.92. Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy.
Will SRPT Get Buyers Even After The Recent Rally? Find Out Here
Horizon Pharma Inc(NASDAQ:HZNP) exchanged 1.54 million shares in the previous trading session, and its average trading remained 1.98 million shares. HZNP advanced 1.33% and it closed the trading at $7.62. The market capitalization of the stock remained 501.84 million. Horizon Pharma, Inc., a specialty pharmaceutical company, through its subsidiaries, develops and commercializes medicines for the treatment of arthritis, pain, and inflammatory diseases. The company was founded in 2005 and is headquartered in Deerfield, Illinois.
For How Long HZNP’s Gloss will Attract Investors? Find out via this report
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)